01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled, crossover, Hungarian Phase II trial to evaluate 75 mg oral CNV2197944 thrice daily for 3 weeks in about 165 DPN patients. As part of its restructuring...
07:00 , Sep 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Calcium channel voltage-dependent N type-a 1B subunit (CACNA1B; CaV2.2); collapsin response mediator protein-2 (DPYSL2; CRMP-2) In vitro and rat studies suggest inhibiting the interaction...
07:00 , May 23, 2011 |  BioCentury  |  Regulation

For want of a nail

See Sidebar: Horizons beyond Horizant FDA 's handling of an NDA for Horizant gabapentin enacarbil looked like exactly the kind of thing that provides grist to critics who say the agency is needlessly delaying access...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Schizophrenia Calcium channel voltage-dependent N type-a 1B subunit (CACNA1B; Cav2.2); double C2-like domains-a (DOC2A); ret proto-oncogene (RET); ras-like without CAAX 2 (RIT2) Genomewide copy number...
08:00 , Jan 14, 2005 |  BC Extra  |  Company News

Scion names Berkowitz CEO

Scion (Medford, Mass.) hired Barry Berkowitz as president and CEO. He replaces Pravin Chaturvedi, who will serve as a consultant to the company. Previously, Berkowitz was corporate VP at Albany Molecular Research (AMRI). Scion is...
07:00 , Sep 22, 2003 |  BioCentury  |  Product Development

Painfully slow

Pain is an underserved market because the use of opioid agonists to treat moderate to severe pain is limited by common side effects like grogginess and constipation, the development of tolerance and dependence, and the...